还少丹治疗阿尔兹海默病方证效相应的理论探析与医案举隅
|
摘要
阿尔兹海默病(Alzheimer’s Disease,AD)病因未明,病理机制不详,中西医治疗方案均未明确有阻断AD病程的方药。本文详细剖析了AD的临床症状并结合中医大家观点,提出衰老是AD发病的主要病因,脏腑亏虚、髓海失养是基本病机,肝脾肾亏虚、心神失养为本,痰浊、血瘀为标,并结合已故国医大师郭子光教授采用还少丹治疗AD的临床验案赏析,提出还少丹在临床早期干预AD,延缓该病进程上具有潜在价值,为临床防治AD提供新的思路。
The etiology of Alzheimer's disease(AD) is unknown, and the pathological mechanism is unclear. The traditional Chinese and Western medicine treatment programs have not clearly defined the prescription for blocking the course of AD. This article analyzed the clinical symptoms of AD in detail and combines the views of Chinese medicine practitioners. It is proposed that aging is the main cause of AD. The viscera deficiency and medullary dystrophy are the basic pathogenesis. The liver, spleen, kidney and mind deficient dysfunctional is essence, and turbidity and blood stasis as the standard, combined with the late traditional Chinese medicine master Professor Guo Ziguang to use the clinical examination of the treatment of AD with Huanshao mini-pills, and proposed that Huanshao mini-pills has potential value in the early stage of clinical intervention of AD, delaying the progress of the disease, and providing clinical prevention and treatment of AD.
The etiology of Alzheimer's disease(AD) is unknown, and the pathological mechanism is unclear. The traditional Chinese and Western medicine treatment programs have not clearly defined the prescription for blocking the course of AD. This article analyzed the clinical symptoms of AD in detail and combines the views of Chinese medicine practitioners. It is proposed that aging is the main cause of AD. The viscera deficiency and medullary dystrophy are the basic pathogenesis. The liver, spleen, kidney and mind deficient dysfunctional is essence, and turbidity and blood stasis as the standard, combined with the late traditional Chinese medicine master Professor Guo Ziguang to use the clinical examination of the treatment of AD with Huanshao mini-pills, and proposed that Huanshao mini-pills has potential value in the early stage of clinical intervention of AD, delaying the progress of the disease, and providing clinical prevention and treatment of AD.
引文
[1]Riemenschneider M,Lautenschlager N,Wagenpfeil S,et al.Cerebrospinal fluid tau and betaamyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment[J].Arch Neurol,2002;59(11):1729-1734.
[2]Joshi P,Benussi L,Furlan R,et al.Extracellular Vesicles in Alzheimer's Disease:Friends or Foes?Focus on Aβ-Vesicle Interaction[J].Int J Mol Sci,2015,16(3):4800-4813.
[3]孙磊,杨莹,窦彩艳.阿尔兹海默病治疗的研究进展[J].医学信息网,2010(7):1969-1970.
[4]宋昕,洪羽蓉,胡秋莹.阿尔兹海默病发病原因及机制的研究进展[J].临床和实验医学杂志,2015,10(14):871-873.
[5]李剑颖.国医大师验案良方·心脑卷[M].北京:学苑出版社,2010:328.
[6]王永炎.关于提高脑血管疗效难点的思考[J].中国中西医结合杂志,1997,17(4):195-196.
[7]高尚社.国医大师张琪教授治疗痴呆验案赏析[J].中国中医药现代远程教育,2013,11(21):10-12.
[8]刘淑红,高尚社.国医大师裘沛然教授辨治痴呆验案赏析[J].光明中医,2011,26(9):1764-1767.
[9]衡先培,孙鸿辉.张发荣论治老年期痴呆的经验[J].四川中医,1997,2(15):4-5.
[10]马洪明.田金洲教授学术思想与临床经验总结及其治疗阿尔茨海默病用药规律研究[D].北京:北京中医药大学第五批全国老中医药专家学术经验继承工作临床医学专业硕士学位论文:2016.
[11]卢灿辉,林汉平,卢有祥,等.卢永兵主任医师治疗老年性痴呆经验介绍[J].新中医,2008,1(40):15-16.
[2]Joshi P,Benussi L,Furlan R,et al.Extracellular Vesicles in Alzheimer's Disease:Friends or Foes?Focus on Aβ-Vesicle Interaction[J].Int J Mol Sci,2015,16(3):4800-4813.
[3]孙磊,杨莹,窦彩艳.阿尔兹海默病治疗的研究进展[J].医学信息网,2010(7):1969-1970.
[4]宋昕,洪羽蓉,胡秋莹.阿尔兹海默病发病原因及机制的研究进展[J].临床和实验医学杂志,2015,10(14):871-873.
[5]李剑颖.国医大师验案良方·心脑卷[M].北京:学苑出版社,2010:328.
[6]王永炎.关于提高脑血管疗效难点的思考[J].中国中西医结合杂志,1997,17(4):195-196.
[7]高尚社.国医大师张琪教授治疗痴呆验案赏析[J].中国中医药现代远程教育,2013,11(21):10-12.
[8]刘淑红,高尚社.国医大师裘沛然教授辨治痴呆验案赏析[J].光明中医,2011,26(9):1764-1767.
[9]衡先培,孙鸿辉.张发荣论治老年期痴呆的经验[J].四川中医,1997,2(15):4-5.
[10]马洪明.田金洲教授学术思想与临床经验总结及其治疗阿尔茨海默病用药规律研究[D].北京:北京中医药大学第五批全国老中医药专家学术经验继承工作临床医学专业硕士学位论文:2016.
[11]卢灿辉,林汉平,卢有祥,等.卢永兵主任医师治疗老年性痴呆经验介绍[J].新中医,2008,1(40):15-16.